Outcomes
thrombosis, death, IDA
THROMBOSIS, MYOCARDIAL INFARCTION, STROKE
The primary efficacy endpoint was to compare mean monthly doses of ESA at month 12 between the two groups. Secondary efficacy endpoints were the incidence of death, myocardial infarction, stroke, IDA, blood transfusion, quality of life, and changes in Hb, ferritin levels, TSAT, and ESA doses.Safety parameters were evaluated throughout the study, including the incidence of vascular thrombosis, hospitalization, and iron withholding rate.